Literature DB >> 18465266

Acute and subchronic (28-day) oral toxicity study in rats fed with novel surfactants.

Ranjit Madhukar Bidhe1, Sangita Ghosh.   

Abstract

The toxicity of 2 new synthetic lipids, 1,2-dioleoyl-rac-glycerol-3-dodecaethylene glycol, GDO-12 (lipid 1) and 1,2-distearoyl-rac-glycerol-3-dodecaethylene glycol, GDS-12 (lipid 2) has been evaluated in acute and subchronic toxicity studies. Acute oral toxicity studies in male and female rats documented no deaths or treatment-related signs at high doses. The lipids were individually administered (by gavage) to male and female Sprague-Dawley rats at concentrations of 250, 500, and 1000 mg/Kg bodyweight for 28 days. All animals survived the duration of the study, with no significant changes in clinical signs, hematological parameters, organ weights, ophthalmology evaluations, or histopathological findings. These studies establish that both GDO-12 (lipid 1) and GDS-12 (lipid 2) are nontoxic in rats following oral administration. The no-observed-adverse-effect level ranged between 250 mg/Kg and 1000 mg/Kg following oral administration.

Entities:  

Year:  2004        PMID: 18465266      PMCID: PMC2751243          DOI: 10.1208/ps060214

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  19 in total

Review 1.  Therapeutic index of H1-antihistamines: example of cetirizine.

Authors:  J P Rihoux
Journal:  Ann Allergy Asthma Immunol       Date:  1999-11       Impact factor: 6.347

2.  Topical application of liposomally entrapped cyclosporin evaluated by in vitro diffusion studies with human skin.

Authors:  K Egbaria; C Ramachandran; N Weiner
Journal:  Skin Pharmacol       Date:  1991

3.  Topical delivery of ciclosporin: evaluation of various formulations using in vitro diffusion studies in hairless mouse skin.

Authors:  K Egbaria; C Ramachandran; N Weiner
Journal:  Skin Pharmacol       Date:  1990

4.  Lipophilicity behaviour of the Zwitterionic antihistamine cetirizine in phosphatidylcholine liposomes/water systems.

Authors:  G Plember van Balen; G Caron; G Ermondi; A Pagliara; T Grandi; G Bouchard; R Fruttero; P A Carrupt; B Testa
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

5.  Destabilization of egg lecithin liposomes on the skin after topical application measured by perturbed gamma gamma angular correlation spectroscopy (PAC) with 111In.

Authors:  R Schubert; M Joos; M Deicher; R Magerle; J Lasch
Journal:  Biochim Biophys Acta       Date:  1993-08-15

6.  Free versus liposome-encapsulated lignocaine hydrochloride topical applications.

Authors:  M S el-Ridy; R M Khalil
Journal:  Pharmazie       Date:  1999-09       Impact factor: 1.267

Review 7.  Cetirizine/pseudoephedrine.

Authors:  K Wellington; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Preparation, optimization, characterization, and stability studies of salicylic acid liposomes.

Authors:  S S Bhalerao; A Raje Harshal
Journal:  Drug Dev Ind Pharm       Date:  2003-04       Impact factor: 3.225

9.  Quantitation of H1-receptor antagonists in skin and serum.

Authors:  F E Simons; H E Murray; K J Simons
Journal:  J Allergy Clin Immunol       Date:  1995-03       Impact factor: 10.793

10.  Manganese-based liposomes. Comparative approaches.

Authors:  E Unger; T Fritz; D K Shen; G Wu
Journal:  Invest Radiol       Date:  1993-10       Impact factor: 6.016

View more
  2 in total

1.  Sub-chronic safety evaluation of aqueous extract of Alangium salvifolium (L.f.) Wangerin leaves in rats.

Authors:  Bhupinder Kapoor; Gagandeep Kaur; Mukta Gupta; Reena Gupta
Journal:  J Adv Pharm Technol Res       Date:  2017 Jul-Sep

2.  Antidiarrheal Activity of Dissotis multiflora (Sm) Triana (Melastomataceae) Leaf Extract in Wistar Rats and Subacute Toxicity Evaluation.

Authors:  Alian Désiré Afagnigni; Maximilienne Ascension Nyegue; Chantal Florentine Ndoye Foe; Youchahou Njankouo Ndam; Frédéric Nico Njayou; Marie Christine Fonkoua; François-Xavier Etoa
Journal:  Evid Based Complement Alternat Med       Date:  2017-11-05       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.